These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 18398615)

  • 1. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
    Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
    Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
    Widmer N; Decosterd LA; Csajka C; Leyvraz S; Duchosal MA; Rosselet A; Rochat B; Eap CB; Henry H; Biollaz J; Buclin T
    Br J Clin Pharmacol; 2006 Jul; 62(1):97-112. PubMed ID: 16842382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
    J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
    Russell MA; Carpenter MW; Akhtar MS; Lagattuta TF; Egorin MJ
    J Perinatol; 2007 Apr; 27(4):241-3. PubMed ID: 17377606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
    Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
    Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
    Boddy AV; Sludden J; Griffin MJ; Garner C; Kendrick J; Mistry P; Dutreix C; Newell DR; O'Brien SG
    Clin Cancer Res; 2007 Jul; 13(14):4164-9. PubMed ID: 17634544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.